BioInvent International AB
The answer first
Does BioInvent International beat the market?
No, BioInvent International has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 50% of Nordic stocks
- Quality86
- Value68
- Trend4
No. 59 of 195 in healthcare
Max for seven days
Follow BioInvent International with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about BioInvent International
Your first answer is free, no account needed.
Do you own BioInvent International, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with BioInvent International and a few more. Free, no card.
Super Stock+46.4%In short
- BioInvent International has fallen 93.1% over the past year, including dividends.
- Overall, BioInvent International ranks better than 50% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 95.7%. The price is 99.8% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 50% of Nordic stocks.
No. 59 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 43 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.14
- Asset turnoverSales divided by everything the company owns0.13
- Return on equityProfit divided by equity−242.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 22 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.7
- P/SPrice divided by sales3.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 181 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−91.1%
- 6 months−92.5%
- 9 months−92.0%
- 12 months−93.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own BioInvent International
11 funds we follow own BioInvent International. The share is how much of the fund the stock makes up.
- Sweden11
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo1.1%
- PLUS Mikrobolag Sverige IndexSweden · PLUS1.0%
- PLUS Hälsovård Sverige IndexSweden · PLUS0.5%
- HealthInvest Small & MicroCap Fund CSweden · HealthInvest0.5%
- HealthInvest Small & Mid Cap Healthcare ESweden · HealthInvest0.5%
- Öhman Sweden Micro Cap ASweden · Öhman0.3%
- Öhman Småbolagsfond ASweden · Öhman0.2%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
From the funds' latest known holdings.
About BioInvent International
BioInvent International AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, BioInvent International is number 79 of 137 companies in healthcare on Nasdaq Stockholm. BioInvent International has not paid a dividend in the past twelve months. Of the three measures in the ranking, BioInvent International is strongest on quality, better than 86% of Nordic stocks. The next report from BioInvent International is expected on 4 March 2027. The share trades in SEK. It has around 110 employees.
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-…


See the full analysis of BioInvent International.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card